Latest Articles
EUTOS Long-Term Survival Score Outperforms Sokal in TKI-Treated CML
EUTOS long-term survival score better predicted prognosis for those with chronic myeloid leukemia who had been treated with TKIs—especially among elderly patients.
Daratumumab Combination: New Standard of Care in Transplant-Ineligible Multiple Myeloma
The findings may support the triplet regimen as a new standard of care for these patients, according to Dr Facon.
The Changing Treatment Landscape for Advanced Renal Cell Carcinoma
Interferon or high-dose interleukin-2 were the only available options for the treatment of metastatic RCC until 2005.
Early-Access Daratumumab Trial Supports Safety in Relapsed, Refractory MM
Researchers also used the trial to collect more information on safety, patient‐reported outcomes, and a specific premedication treatment protocol.
Men With Prostate Cancer Willing to Accept Worse Survival Odds to Improve QoL
Trade-offs should be carefully considered, as data have indicated that many QoL factors eventually even out.
Gender-Based Differences in Chemotherapy: Efficacy and Safety
Women and men were found to react differently to treatment with chemotherapy, although gender-based survival differences were not observed.
Liquid Biopsy as a Surveillance Tool for Breast Cancer Follow-Up
High-risk early breast cancer patients with circulating tumor cells 2 years after chemotherapy had greater risk of recurrence. Possible interventions are needed.
Treatment-Related Hyperprogression: Concerns Continue to Mount
Evidence is growing to support the idea that immune checkpoint inhibitors can speed up tumor growth, although the exact mechanism of how this occurs is still unclear.
Conditional 10-Year Breast Cancer Recurrence Rates Decline Regardless of Subtype
Among 4 specific breast cancer stages, T2N1 cancers showed the highest risk for local recurrence, regional recurrence, and distant metastases within 10 years from diagnosis.
Trials, Collaboration Might Help Reduce Survival Disparities Between Community, Academic Cancer Centers
Better collaboration between community and academic cancer centers could benefit patients.
New Algorithm Improves Outcome Prediction for Diffuse Large B-Cell Lymphoma
The model was developed using machine learning techniques and programmed with data from a Danish cancer registry.
Moving Targets: Off-Label Prescribing of Targeted Therapies
By way of the TAPUR study, researchers are attempting to evaluate the activity of targeted therapies when they are used in an off-label setting.
2-Year TKI Consolidation Allowed for TKI Cessation in Select Patients With CML
The majority of patients studied who stopped TKI therapy remained treatment-free at 3 years.
Encorafenib Plus Binimetinib Offers a New Option for MEK+BRAF Inhibition
In the immunotherapy era, the optimal setting and sequencing of BRAF+MEK inhibition remains unresolved.
Proteomics Study Reveals New Medulloblastoma Subtypes and Potential Novel Treatment Targets
Genomic and proteomic studies of medulloblastoma samples helped researchers characterize new cancer subtypes and targets.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
| Bone Cancer | Regimens | Drugs |
| Brain Cancer | Regimens | Drugs |
| Breast Cancer | Regimens | Drugs |
| Endocrine Cancer | Regimens | Drugs |
| Gastrointestinal Cancer | Regimens | Drugs |
| Gynecologic Cancer | Regimens | Drugs |
| Head and Neck Cancer | Regimens | Drugs |
| Hematologic Cancer | Regimens | Drugs |
| Lung Cancer | Regimens | Drugs |
| Other Cancers | Regimens | |
| Prostate Cancer | Regimens | Drugs |
| Rare Cancers | Regimens | |
| Renal Cell Carcinoma | Regimens | Drugs |
| Skin Cancer | Regimens | Drugs |
| Urologic Cancers | Regimens | Drugs |
Cancer Therapy Advisor Articles
- CAR-T Trial for Triple-Negative Breast Cancer Under Way
- Adjuvant Trastuzumab Emtansine Confers Improved Outcome in KATHERINE Trial
- Phase 3 GEICAM/CIBOMA Results: Adjuvant Capecitabine in Triple-Negative Breast Cancer
- Rivaroxaban Reduced VTE and VTE-Related Death in Patients With Cancer: Results of the CASSINI Study
- CAR-T and Ibrutinib: Better Together?
- Risk Score Identifies Adjuvant Chemotherapy Toxicity Risk in Elderly Patients With Breast Cancer
- Despite Breast-Conserving Surgery Eligibility, Nearly 50% of Women Chose Mastectomy
- Lisinopril and Carvedilol May Reduce Cardiotoxicity During Adjuvant Trastuzumab Treatment
- Immune Marker Identified as Prognostic in Triple-Negative Breast Cancer
- Rates of Adverse Events Similar Regardless of IMRT Boost Type